Podcasts about ASO

In this talk at AppsFler MAMA SF 2026, Steve P. Young breaks down the latest app monetization strategies that are actually working in 2026, including onboarding paywalls, paid intro offers, reverse trials, hard paywalls, discount pricing psychology, and subscription optimization.Drawing from real app case studies and experiments, Steve shares actionable tactics that have helped apps dramatically increase trial activations, trial-to-paid conversion rates, retention, and overall revenue.If you're building a subscription app, SaaS app, AI app, or mobile startup, this session is packed with practical insights you can implement immediately.You'll Learn:✅ Why your paywall should be inside onboarding✅ The “3 Screen Paywall” strategy is increasing trials by 56%+✅ Paid intro offers vs free trials✅ Reverse trials that boosted conversions 10X✅ Discount pricing psychology that increases revenue✅ Real monetization experiments from top appsWhether you're focused on ASO, user acquisition, subscriptions, retention, or app growth, these monetization insights can help you scale faster.

Jani Torppa is the co-founder and COO of Geeklab, the go-to UA and ASO platform for mobile game studios looking to grow smarter. Since starting the company in 2019, Jani's been hands-on in making sure things run smoothly, driving the business forward, and working closely with the biggest names in gaming.

This week's new albums: Little Barrie | Elder Island | Elder Also: Vibe restorers, three-act festivals, too big for small rooms, screen assists, whither hammock time, underproduction values, late night brown spirts albums, getting dragged to Woodford, Legacy Slop Watch, ghosts of girlfriends past, bio-engineering, reclaiming our status as Australasia's most Knicks-positive NBA-adjacent podcast, early red mist, Mike Brown Appreciation Hour, it's all Bill Simmons' fault, France play football now?, your first World Cup, ASO v ACO and prevailing over the profiteers. 3:26  Elder6:19  Elder Island9:49  Little Barrie18:34  Next week's albums 27:48  After Dark - NBA finals, kids' football, World Cup Next week's new albums: Modern Woman | SLIFT | Ben KidsonSpotify playlists: Album review playlist | Doc's and Beeso's 2026 mixtapes | All our playlistsThe list: Our previous review albums and year-end top fivesFind us on: Spotify Podcasts | Apple Podcasts | RSS feed for other appsSocials: Beeso on Bluesky | Doc on BlueSky | Pod Facebook | Pod email

Generative Engine Optimization, or more commonly known as AI search, is reshaping app discovery faster than most founders realize.In this episode, we are joined by David Andersen, Co-Founder & CTO of BrandViz.AI and former Google engineer, to explore how Generative Engine Optimization (GEO) is reshaping app visibility across ChatGPT, Gemini, Claude, Perplexity, and more.As more users ask AI tools for recommendations, app makers need to understand how these systems choose which apps and brands to surface.David shares practical strategies app founders can implement immediately to improve visibility across AI-powered search experiences, and how GEO can complement your ASO.David will also share practical strategies app founders can implement immediately, plus real-world examples and a live visibility audit for some apps.You will discover:✅ How ChatGPT, Gemini & Claude recommend apps✅ The future of AI-powered app discovery✅ Practical GEO strategies app makers can implement this week✅ What changes over the next 12–24 months as AI reshapes searchLearn More:Check out: https://www.brandviz.ai/Work with us to grow your apps faster & cheaper:http://www.appmasters.com/You can also watch this video here: https://youtube.com/live/lRbvILrIcG0*********************************************SPONSORSThe app growth playbook is changing fast.AppsFlyer's State of eCommerce App Marketing Report 2026 breaks down the latest trends, benchmarks, fraud insights, and market-by-market data every app marketer should know before planning Q4.Download it free from the link below: https://bit.ly/4uvoHGM*********************************************Yango Ads is offering 20% revenue boost bonus, sign up here: https://yango-ads.com/adnetwork/bonus20?utm_source=yt&utm_medium=social&utm_campaign=bonus. This special offer is valid before June 30th, 2026. Don't miss your chance to monetize your apps smarter!*********************************************Follow us:YouTube: ⁠AppMasters.com/YouTube⁠Instagram: ⁠@App MastersTwitter: ⁠@App MastersTikTok: ⁠@stevepyoung⁠Facebook: ⁠App Masters⁠*********************************************

How does an ASO specialist with 10+ years of experience think about AI visibility in 2026?In this episode of Intelligent Artifice, Simon Thillay from AppTweak shares what the data actually shows about how AI tools like ChatGPT are discovering and recommending apps today. ChatGPT owns the platform. Grammarly is outranking it inside its own answers. Simon knows exactly why.This conversation covers what is actually changing in app store optimization, how AI visibility works differently from traditional ASO, and why the gap between apps that show up in AI-generated answers and those that don't is already opening up.AppTweak's research found that the most cited domain in ChatGPT answers for app-related queries is the App Store itself. Simon's team tested the same intent across ten different phrasings and found Grammarly consistently outranking ChatGPT for business writing app recommendations inside ChatGPT. The difference was not product quality. It was how Grammarly positioned itself for specific user contexts across its app store presence.Simon also points to one specific part of the App Store listing that most ASO teams have never touched, and explains why it is now one of the strongest levers for AI visibility in 2026.Video Chapters:00:00 – Introduction & Podcast Technical Mishaps 00:46 – How AI is Changing App Store Visibility 01:42 – Pre-searching Apps via LLMs (ChatGPT Traffic) 02:14 – The Role of App Store Optimization (ASO) in AI Answers 02:40 – Optimizing Long Descriptions for AI Search 03:19 – Writing for Humans vs. Writing for AI (User Personas) 04:08 – Structuring Content & Entity-Based Writing for AI 05:07 – Answer Engine Optimization (AEO) & The Open Web Ecosystem 06:26 – How to Audit Your App's AI Visibility (Intent vs. Prompts) 07:11 – Case Study: Grammarly Outperforming ChatGPT on Niche Intents 07:54 – Measuring AEO Impact: Coverage, Rank, and Sentiment 09:02 – Where to Find Simon ThillayTopics covered:App Store optimization and AI visibility in 2026How ChatGPT and LLMs discover and recommend appsAEO strategy for mobile appsEntity-based writing for app store listingsMeasuring AI visibility across coverage, rank, and sentimentAppTweak research on AI-driven app discoveryLearn more: https://mobileuseracquisitionshow.com/episode/aso-for-ai-simon-thillay/- Episode pagehttps://www.linkedin.com/in/simon-thillay-58b95997/- Connect with Simon on LinkedIn

Griffin just handed $100M to indie developers, Lilith is back with a pachinko creature collector that's turning heads, and Toon Blast hired Gus Fring for reasons that actually make sense.In this episode, we break down:● Griffin Gaming Partners' $100M indie fund and why project financing beats VC math for games● Why the tourists are gon,e and the OG gaming VCs are back● Embracer's endless restructuring and the Fellowship Entertainment spin-off● The full Embracer collapse timeline, 44 studios closed, 80 projects canceled● Google Play's AI-powered game discovery and what it means for your ASO strategy● Why keyword stuffing is dead and how to write for Gemini● Clash of Critters: Lilith's pachinko-core creature collector and the casualization of mid-core● Why Chinese studios didn't invent advanced casual — they just perfected it● Monopoly Go's decline and what levers Scopely has left● Coin Master Board Adventure vs Monopoly Go, is there any real competition?● Toon Blast's Gus Fring campaign and whether celebrity UA still moves the needle● Why re-onboarding lapsed players matters as much as acquiring new onesCHAPTERS:01:39 Banter Roblox and Xbox Takes02:47 Roundtable Events and Consulting Talk05:14 Quick Correction It Takes Two07:20 Google I O Play Updates10:58 ASO SEO for AI Debate14:01 Griffin Fund for Indies17:57 Why VC Math Broke21:10 Embracer Splits Again24:13 Embracer Fallout and Asset Timeline29:02 Mobile Game Data Setup29:30 Lilith Clash of Critters Deep Dive30:25 Portfolio Reality Check30:49 Grim Metrics Decline31:33 Pachinko Creature Collector32:35 Gacha And Meta Layers35:27 Why It Works Now38:01 Advanced Casual Debate41:19 Graphics And Monetization44:25 Coin Master Vs Monopoly Go48:08 Franchising And Growth Levers55:38 Toon Blast Celebrity UA01:00:21 Wrap Up And Next Week

In this episode, Dr. Paloma Giangrande, Editor-in-Chief of Molecular Therapy Nucleic Acids, speaks with Normand Allaire, Head of Genomics at the Cystic Fibrosis Foundation Therapeutics Lab. They discuss the article, Upregulation of a CFTR mRNA isoform has therapeutic potential for the treatment of 3’ CFTR PTC variants, which introduces an ASO-based therapeutic approach to cystic fibrosis for the 10% of patients who lack an approved treatment. Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

On Tuesday's "Dan O'Donnell Show," Dan runs down the biggest left-wing media narratives of the day: From the Watertown symphony controversy to Tom Tiffany and the 2020 election to Tiffany's role in the defeat of the budget surplus bill. Aso, a big announcement in the 4:00 hour to say thank you to the show's fans!See omnystudio.com/listener for privacy information.

In this solo episode, Steve P. Young breaks down the latest trends in app monetization and distribution, sharing insights from recent industry discussions, including key takeaways from the Business of Apps event.Steve will also answer audience questions related to apps, business growth, monetization, and scaling strategies, and share practical insights you can apply immediately to increase downloads, improve retention, and grow revenue.Whether you're a founder, indie developer, or growth marketer, this episode will help you refine your onboarding flow, paywall strategy, and pricing model for better conversion and long-term success.You'll learn how to build a high-performing strategy around:✅ Onboarding optimization✅ Pricing strategy for apps✅ Distribution channels (ASO, paid ads, partnerships)✅ User acquisition trends✅ Industry shifts shaping 2026Learn More:Join the App Founder's Community:https://appfounders.co/Work with us to grow your apps faster & cheaper:https://www.appmasters.com/You can also watch this video here: https://youtube.com/live/sqopVyCWzYo*********************************************SPONSORSWant to know what ads your competitors are running right now?SocialPeta gives you access to real ad creatives and market insights across apps, games, and emerging content formats, so you can stay ahead without endless trial and error.Check it out at https://www.socialpeta.com/*********************************************Ready to take action? Start exploring AppsFlyer's deep linking suite -  coming soon as a standalone solution, independent of their measurement packages → ⁠https://bit.ly/46O7Wgd*********************************************Follow us:YouTube: ⁠AppMasters.com/YouTube⁠Instagram: ⁠@App MastersTwitter: ⁠@App MastersTikTok: ⁠@stevepyoung⁠Facebook: ⁠App Masters⁠*********************************************

Friday, May 8, 2026 - Week 19   CURE SYNGAP1 STRATEGY WORKING Our strategy has always been to derisk SYNGAP1 so that industry will invest and bring their skill and capital to bear.  We leverage donor dollars to maximize impact.  Yesterday was a great example:   EARNINGS REPORTS CAMP4 1Q26 Results: $99M https://investors.camp4tx.com/news-releases/news-release-details/camp4-reports-first-quarter-2026-financial-results-and-corporate We submitted our first regulatory filing for CMP-002 in Australia which positions us to initiate a global first-in-human Phase 1/2 clinical trial in the second half of 2026.   Stoke 1Q26 Results: $411M https://investor.stoketherapeutics.com/news-releases/news-release-details/stoke-therapeutics-announces-first-quarter-2026-financial  Lead optimization is underway to identify a clinical candidate for the treatment of SYNGAP1 in 2026. SYNGAP1 is a severe and rare genetic neurodevelopmental disease.   Praxis 1Q26 Results: $1.4B https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-19  Praxis remains on track to nominate a development candidate for each of its three early stage ASO therapeutic initiatives in the first half of 2026:  PRAX-090 is designed to address SYNGAP1 loss-of-function (LoF) mutations, a leading cause of severe intellectual disability and epilepsy in DEEs.   #CompetitionIsGoodForThePatient    KCNT1 Big Day today - Congratulations Post: https://www.linkedin.com/posts/graglia_kcnt1-share-7458560855744618496-X10d Press Release: https://www.linkedin.com/posts/kcnt1-kcnt1-epilepsy-ugcPost-7458487179149787136-kH7c/   WATCH & SHARE OUR VIDEO Watch and share the new SYNGAP1 Video, it is excellent and helps explain our cause to families and friends.  We need to turn them into supporters and donors. cureSYNGAP1.org/SYNGAP1 -> https://youtu.be/pO3ayASBiEk   INAUGURAL SF NIGHT OF IMPACT, CA – 20 days Join us this is our only Gala for 2026! cureSYNGAP1.org/SF26   5TH SCRAMBLE FOR SYNGAP, SC – 148 days Classic case of a small event becoming an institution! cureSYNGAP1.org/Scramble26   USA: use your ICD-10, F78.A1: https://onlinelibrary.wiley.com/doi/10.1002/epi.70142   PUBMED Pubmed 2026 is at 28. +9 vs the week. (61 last year was +9) https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.2026-2026&sort=date   https://pubmed.ncbi.nlm.nih.gov/42093631/ ADHD in patients with #DLG2 #NRXN1 #SHANK3 #SYNGAP1   SOCIAL MATTERS 4,940 LinkedIn.  https://www.linkedin.com/company/curesyngap1 1,569 YouTube.  https://www.youtube.com/@CureSYNGAP1 11.1k Twitter https://twitter.com/cureSYNGAP1 45k Insta https://www.instagram.com/curesyngap1   $CAMP closed at $4.46. https://www.google.com/finance/beta/quote/CAMP:NASDAQ $STOK closed at $32.89. https://www.google.com/finance/beta/quote/STOK:NASDAQ $ACAD closed at $22.40. https://www.google.com/finance/beta/quote/ACAD:NASDAQ $PRAX closed at $330.02. https://www.google.com/finance/beta/quote/PRAX:NASDAQ   Like and subscribe to this podcast wherever you listen. https://curesyngap1.org/podcasts/syngap10 Episode 207 of #Syngap10 #SYNGAP1 #CureSYNGAP1 #Podcast #PatientAdvocacy

I came up with at least one way to tell the difference between making a fair profit and profiteering. If someone makes more money when the patients or members they serve are worse off, yeah, call that profiteering. For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. For more on what is fair profit versus what is profiteering, I would recommend you go back and listen to the episodes on mission and margin with Ben Schwartz, MD, MBA (EP481) and then with Mick Connors, MD (EP495). But it's probably not an accident that I have started an episode about Medicare Advantage in this fashion. To this end, I am very much looking forward to hearing what's up with Medicare Advantage from the one and only Betsy Seals, who is back for her third appearance on Relentless Health Value. And her advice in a nutshell is this: Don't profiteer. There are ample ways to make a fair profit. Just go back to basics and do it the right way. I wanna kind of tick through the list of things that I think about when I think about Medicare Advantage and just how it is relevant to absolutely everybody. The first thing I think about when I think about Medicare Advantage—and this is very obvious—is what Medicare Advantage plans do or don't do are our tax dollars at work or not at work, as the case may be. Along these same lines, the second thing: How does this impact our elders, our family, our friends, our grandparents? These are our senior citizens, getting the care or not getting the care that they may need. Those two are obvious. Now let's talk about a few less obvious things. Here's the third point that I think about as I listen to conversations about Medicare Advantage: cost shifting. Right? It is a well-known fact how big, vertically integrated carriers—and when I say big, vertically integrated carriers, I mean ones that have a Medicare Advantage line of business—when negotiating with big, consolidated health systems, the release valve of those negotiations is commercial rates. These are the rates that the self-insured employers are paying. So, the carrier says, "Look, gimme the best Medicare Advantage rates. I want the best Medicare Advantage rates because I, the carrier, am paying for those." Savings from those lower rates accrues to the Medicare Advantage plan and its shareholders or investors or executives, right? So, the carrier with the Medicare Advantage plan is like, "Look, go as low as we can go on the Medicare Advantage rates, but it's okay, health system, if you make up the difference with the ASO commercial book of business." Because right … ASO means administrative services only. It's not the carrier who's paying those commercial rates at the end of the day. So, the carrier uses its full book of business to negotiate lower rates for itself while, at the same time, cost shifting to commercial members. In fact, there was some research that was cited. It was episode 436 with Elizabeth Mitchell, and I quoted Luke Prettol. But there was research that puts this markup at 4.7% above what employers would otherwise pay if they had an ASO that did not have a Medicare Advantage Plan. So, yeah … number three big thing that I think about when listening to MA insights like the ones that Betsy drops today, I think about will this accelerate or ameliorate or really have anything to do with what is going on around those negotiating tables with ASOs and health systems? Because let's not forget, health systems account for about 50% of most self-insured employers' total health spend. The fourth thing that I think about: Will MA carriers underpay independent practices, especially primary care practices? Will it pay indies less? And then if it pays 'em a lot less, would ultimately manage to put them out of business, ultimately raising the total cost of care for everybody. But if we're thinking about this strictly from Medicare Advantage financial perspective, a really great move here, these are big, vertically integrated companies, don't forget. Many of them own provider organizations. This is why the FTC tends to frown on vertical integration. So, will these Medicare Advantage organizations who own provider organizations pay the provider organizations they own more? By the way, it's the same thing that's going on on the pharmacy side of the house when a PBM pays pharmacies that they own more. Here's a LinkedIn post by Stanley Warren about this topic. And there are a lot of obvious, maybe less obvious reasons for why paying providers the carrier itself owns more is a great short-term move. One of them is intracompany eliminations. Listen to the episode with Preston Alexander (EP482). But here's another reason: Rate increases paid by the government for Medicare Advantage plans are based on fee-for-service benchmarks. So, if fee-for-service rates go up, then the Medicare Advantage plans can negotiate more money for themselves. If the MA plans own the providers that are charging said FFS rates, then this is, I don't know, a great strategy, especially given the lobbying budget that some of these entities have. So, look … on today's show, I get the distinct opportunity to speak with Betsy Seals, my guest today, as I mentioned earlier; and we go through her advice for MA plans and what they need to get busy with and ensure, make a fair profit, go back to basics, and do it the right way. That's her bottom-line advice. Don't be putting your hands in the cookie jar. Sooner or later, you're gonna get caught. Focus on the members that you're really good at serving. And lastly, when it comes to STARS or other quality measures, lift them the right way—like, actually through better member health and actually better member experience, not some engineered mechanism by which one can check a box that honestly doesn't deserve to get checked. Because now we're back to the beginning and you're gonna get caught with your hand in the cookie jar, and it's profiteering. Let's just get real about that. If somebody's checking boxes that they don't deserve to check, member health is not improving. Betsy Seals, my guest today, as I have said at least three times, co-founded Rebellis Group, which is a Medicare Advantage consultancy. She became CEO of its parent company, Alerion Advisors. Now she is a board member, and also she works with start-ups in our industry. This podcast is sponsored by Aventria Health Group with an assist today from Payerset to help us with the financial support that we need to stay on the air. And with that, here is my conversation with Betsy Seals. Also mentioned in this episode are Alerion Advisors; Rebellis Group; Benjamin Schwartz, MD, MBA; Mick Connors, MD; Elizabeth Mitchell; Luke Prettol; Luke Trocchio; LoVasco; Stanley Warren; Preston Alexander; Aventria Health Group; Payerset; Eric Bricker, MD; Scott Conard, MD; Bob Herman; and Vivian Ho, PhD. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here.   You can learn more by visiting the Rebellis Group blog and by connecting with Betsy on LinkedIn. You can also email her at bseals@rebellisgroup.com.     Betsy Seals is the co-founder of Rebellis Group, former CEO of Rebellis Group and Alerion Advisors, and a current board member of the Alerion Advisors family of companies. With over 25 years of experience across Medicare and Medicaid programs, Betsy is a nationally recognized leader known for her regulatory expertise, strategic vision, and ability to deliver measurable results. Betsy's work spans mergers and acquisitions, compliance, enterprise strategy, sales and marketing, supplemental benefits, and innovative benefit design that optimizes health plan performance and improves health outcomes. Betsy brings a strong blend of executive leadership, business acumen, and deep regulatory knowledge, with a focus on driving operational excellence and meaningful member impact.   00:00 Introduction to this episode. 00:43 Past episodes on profiteering: EP481 with Benjamin Schwartz, MD, MBA, and EP495 with Mick Connors, MD. 01:25 How Medicare Advantage is relevant to everyone. 06:15 A preview of today's conversation. 07:49 The "state of the state" of Medicare Advantage plans. 08:49 Video by Eric Bricker, MD, on the financial performance of the U.S. healthcare system. 09:32 Does Medicare Advantage's losses matter to the patients? 10:29 A recap of Betsy's insights so far. 11:19 The underlying strategic through line that needs to be considered. 13:04 The impact of Goodhart's Law. 14:12 What the players that are succeeding right now are doing. 14:22 The first pillar of a back-to-basics strategy: Don't get caught with your hand in the cookie jar. 16:07 EP463 with Betsy Seals. 16:50 Why short-term strategies don't work. 18:26 Stats report on prior authorizations serving the beneficiary. 19:32 EP482 with Preston Alexander. 19:38 Why prior authorization needs change. 21:28 The better strategy to use. 21:43 EP462 with Scott Conard, MD. 23:17 The second pillar of a back-to-basics strategy: Focus on the beneficiaries you actually serve well. 24:37 What it looks like to implement this focus on the beneficiaries you serve well. 25:29 How special needs plans play into this. 27:43 The third pillar of a back-to-basics strategy: Think about how STARS in clinical programs improve health. 30:04 The ethical component to implementing a Medicare Advantage program. 31:04 Betsy's advice for independent practices dealing with prior authorizations. 33:37 STAT article by Bob Herman about the effectiveness of Medicare Advantage lobbying on policy. 34:08 Betsy's final notes for all players impacted by what's currently happening.   @betsyseals discusses the impact of #medicareadvantage news on our #healthcarepodcast. #healthcare #podcast #financialhealth #commercialpayermarketplace #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Patrick Nelli; Lee Lewis; Stacey Richter with 15 experts (EP507); Jerry DiMaso; Dr Ahilan Sivaganesan; Ryan Jacobs; Stacey Richter (INBW46); Ryan Wells, Dr Leo Spector, and Adam Stavisky  

On the eve of the Giro d'Italia, the first grand tour of the cycling year, James Emmett and David Cushnan unpack professional cycling's business model and examine the tensions at the heart of it.Reflecting on James' conversation with INEOS-Grenadiers CCO Tom Hill, they discuss the dominant role of Tour de France-organiser ASO in the sport, and the efforts the UCI WorldTour teams are making to try and grow their own revenues in a sport where sponsorship is particularly critical. They also consider the challenges of building brand equity in teams when team names change so regularly, as sponsors come and go.Elsewhere, there's reaction as UC3, the joint venture between Uefa and European Football Clubs set up to commercialise Europe's club competitions, confirms a raft of fresh media rights agreements for the next cycle. Plus, why the Met Gala is now firmly part of the annual sports calendar.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Brett Monia, Ph.D., CEO at Ionis Pharmaceuticals, talks about how antisense oligonucleotides (ASO) graduated from a late-1980s lab concept to real RNA-targeting medicines, and why Ionis stuck with a difficult modality despite multiple setbacks. Brett describes the company's shift from a partner-first model to building a wholly-owned pipeline, commercial function, and an expanded manufacturing operation, and how he as a founding scientist-turned-CEO bridged a skills gap in finance and investor relations. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Na atoa i le vaiaso talu ai, le Aso 28 Aperila le 30 tausaga o le osofa'iga i Port Arthur, Tasmania. E to'a 35 i latou na maliliu ai ma le to'atele na manunu'a.

Join us for a LIVE coaching call with Gary Levitt, co-founder of Future Moments, where we break down real strategies to grow apps in today's competitive market.Gary Levitt is a musician, audio engineer, comedian, and entrepreneur. He is the co-founder of Future Moments, a company behind 11+ apps designed to help creators improve audio and video production.Today, we're diving deep into what actually works when it comes to app growth, influencer marketing, and scaling across iOS and Google Play.This is not theory, it's a real, behind-the-scenes strategy session. Must-watch session for those who are building an app in 2026. You will discover :✅ How to use influencer marketing to grow your app✅ Key differences between iOS vs Google Play growth strategies✅ How to position and market niche apps in 2026✅ What most app founders get WRONG about growth✅ Live feedback, strategy, and optimization tipsLearn More:Website: https://future-moments.com App Portfolio: https://apps.apple.com/us/developer/future-moments/id895157892 YouTube: https://www.youtube.com/@FutureMoments Twitter/X: https://x.com/garygarylevitt Instagram: https://www.instagram.com/garygarylevittWork with us to grow your apps faster & cheaper:http://www.appmasters.com/You can also watch this video here: ⁠⁠https://youtube.com/live/1Lg8sjqyYXw*********************************************SPONSORSStill designing, resizing, and uploading screenshots manually? AppScreens lets you pick from hundreds of high-converting templates, generate for every device size and language in minutes, and upload automatically to directly to App Store Connect and Google Play Console. Trusted by more than 100K developers and ASO experts worldwide.Try it free: https://appscreens.com/?via=am*********************************************Got tons of freemium users who won't upgrade? Encore turns free users into paying customers and reduces churn by adding smart, curated affiliate offers at key user moments. Everyone wins with Encore.Learn more at ⁠https://encorekit.com/*********************************************Ready to take action? Start exploring AppsFlyer's deep linking suite -  coming soon as a standalone solution, independent of their measurement packages → https://bit.ly/46O7Wgd*********************************************Follow us:YouTube: ⁠AppMasters.com/YouTube⁠Instagram: ⁠@App MastersTwitter: ⁠@App MastersTikTok: ⁠@stevepyoung⁠Facebook: ⁠App Masters⁠*********************************************

Want to know how to actually grow your app with App Store Optimization (ASO)? In this video, you will see Steve do ASO live, so you can see our exact process for optimizing apps for more downloads and revenue.We collaborate with indie developer Flo to audit his app and reveal our full App Store Optimization process, from keyword research to monetization strategy.You'll Learn:✅ The exact ASO framework we use for clients✅ How to choose low competition & high traffic keywords✅ How to increase rankings using data-driven ASO✅ Monetization tips (paywalls, pricing, trials)✅ How to optimize screenshots for higher conversionsKey Takeaways:Most apps don't fail because of bad ideas…They fail because of poor ASO and a weak keyword strategy.This video shows you how to fix that, step by step.Work with us to grow your apps faster & cheaper:http://www.appmasters.com/You can also watch this video here: ⁠⁠https://youtu.be/m09QYqWsodQ*********************************************SPONSORSStill designing, resizing, and uploading screenshots manually? AppScreens lets you pick from hundreds of high-converting templates, generate for every device size and language in minutes, and upload automatically to directly to App Store Connect and Google Play Console. Trusted by more than 100K developers and ASO experts worldwide.Try it free: https://appscreens.com/?via=am*********************************************Got tons of freemium users who won't upgrade? Encore turns free users into paying customers and reduces churn by adding smart, curated affiliate offers at key user moments. Everyone wins with Encore.Learn more at ⁠https://encorekit.com/*********************************************Ready to take action? Start exploring AppsFlyer's deep linking suite -  coming soon as a standalone solution, independent of their measurement packages → https://bit.ly/46O7Wgd*********************************************Follow us:YouTube: ⁠AppMasters.com/YouTube⁠Instagram: ⁠@App MastersTwitter: ⁠@App MastersTikTok: ⁠@stevepyoung⁠Facebook: ⁠App Masters⁠*********************************************

What if the real reason your app isn't growing… isn't your ads, features, or budget, but your understanding of user psychology?In this special birthday episode, we are joined by Colin Hodge, startup founder and growth expert behind apps with 100M+ users, including the Top 10 dating app DOWN, to break down how the best apps in the world actually grow.From launch to retention to revenue, Colin shares the exact psychological frameworks that drive user behavior, and how you can apply them to your own app today.A must-watch session for app founders, product managers, and growth teams who want to understand user psychology and build apps that drive retention, engagement, and revenue.PS: This episode is extra special as both Steve and Colin are celebrating their birthdays, so expect some fun moments along the way!You will discover:✅ The 3 core levers to grow any app (paywalls, monetization, retention)✅ The “Magic Moments” framework that creates addictive user experiences✅ The psychology behind why users stay, pay, and come back✅ Real lessons from scaling apps to millions of usersLearn More:Colin's book: colinhodge.com/book Connect with Colin: linkedin.com/in/ckbhodgeYou can also watch this video here: ⁠https://youtube.com/live/f-K7I3KnFns*********************************************SPONSORSStill designing, resizing, and uploading screenshots manually? AppScreens lets you pick from hundreds of high-converting templates, generate for every device size and language in minutes, and upload automatically to directly to App Store Connect and Google Play Console. Trusted by more than 100K developers and ASO experts worldwide.Try it free: ⁠https://appscreens.com/?via=am*********************************************Want to know what ads your competitors are running right now?SocialPeta gives you access to real ad creatives and market insights across apps, games, and emerging content formats, so you can stay ahead without endless trial and error.Check it out at https://www.socialpeta.com/*********************************************Ready to take action? Start exploring AppsFlyer's deep linking suite -  coming soon as a standalone solution, independent of their measurement packages → ⁠https://bit.ly/46O7Wgd*********************************************Follow us:YouTube: ⁠AppMasters.com/YouTube⁠Instagram: ⁠@App MastersTwitter: ⁠@App MastersTikTok: ⁠@stevepyoung⁠Facebook: ⁠App Masters⁠*********************************************

Three very different Paris-Roubaix debutants share their stories in this month's mini feature. We hear from long-time Classics stalwart Shirin Van Anrooij, youngest finisher Jente Koops and Alexis Magner who comes to the race after recovering from a life-threatening crash last season.Before that, Rose Manley, Denny Gray and Lizzy Banks discuss their big take-aways from the cobbled classics and how the current rider injury list might shape the Ardennes Classics to come.We also delve into the decision by race organisers ASO to move the women's Paris-Roubaix from Saturday to a shared slot with the men on the Sunday. And explore in what ways the race's limited TV coverage could have wider ramifications for the sport.Also on the agenda: Lizzy's many goats, cyclist ribs on the barbecue and hold on, did Denny just quit?EPISODE SPONSORSailyIf you are travelling abroad and want to reduce or even eliminate roaming charges you need an eSim from Saily, brought to you by the creators of NordVPN.⛵Download the SAILY app and use our code cycling at checkout to get an exclusive 15% off your first purchase. Or go to saily.com/cycling for full detailsFollow us on social media:Twitter @cycling_podcastInstagram @thecyclingpodcastFriends of the PodcastSign up as a Friend of the Podcast at thecyclingpodcast.com to listen to new special episodes every month plus a back catalogue of more than 300 exclusive episodes.The 11.01 CappuccinoOur regular email newsletter is now on Substack. Subscribe here for frothy, full-fat updates to enjoy any time (as long as it's after 11am).The Cannibal & BadgerFriends of the Podcast can join the discussion at our new virtual pub, The Cannibal & Badger. A friendly forum to talk about cycling and the podcast. Log in to your Friends of the Podcast account to join in.The Cycling Podcast is on StravaThe Cycling Podcast was founded in 2013 by Richard Moore, Daniel Friebe and Lionel Birnie.

In this episode, we are joined by Josh Peleg, who has deployed over $23M into mobile apps and games, to break down how top app studios are using a Wall Street-style playbook to acquire, grow, and scale apps faster than ever.We go deep into the buy vs build decision, how to spot undervalued apps, and the exact frameworks used to turn small apps into massive revenue drivers.Josh will also share real insights from the frontlines, including how his team scaled an app from 200K to 5M MAU, what most founders get wrong about valuations, and the biggest risks you need to watch out for before acquiring any app.If you're an app founder, indie developer, or investor looking to scale faster, reduce risk, and make smarter growth decisions, this episode is for you.You will discover:✅ Why buying apps can outperform building✅ How to evaluate apps before acquiring them✅ When to double down vs kill an app✅ The full app acquisition process (step-by-step)Learn More:

In this episode, we're joined by Summer Liu, CMO of SocialPeta, one of the leading ad intelligence platforms used by top app developers and marketers worldwide.Summer will break down the latest data from 90K+ advertisers and 1.7B+ ad creatives, revealing what's actually driving installs, revenue, and scale in 2026. She'll also share the trends from AI apps and short drama apps to the top-performing ad creatives and strategies across different markets.Must watch, if you're building, growing an app, or finding what to build next.You will discover:✅ Why micro-drama apps grew 126% YoY and how to replicate their success✅ The rise of AI apps (Chat, Companions) and winning growth angles✅ How to find winning creatives and spy on competitors using SocialPeta✅ Top-performing ad creatives across regions (and why they work)Learn More:Planning to scale your app or game globally?SocialPeta provides deep insights into global advertising trends, localized creatives, and competitive strategies, helping growth teams expand into new markets with confidence.Start your data-driven expansion at https://www.socialpeta.com/.You can also watch this video here: ⁠⁠https://youtube.com/live/_ELbpz39hzE*********************************************SPONSORSStill designing, resizing, and uploading screenshots manually? AppScreens lets you pick from hundreds of high-converting templates, generate for every device size and language in minutes, and upload automatically to directly to App Store Connect and Google Play Console. Trusted by more than 100K developers and ASO experts worldwide.Try it free: https://appscreens.com/?via=am*********************************************Got tons of freemium users who won't upgrade? Encore turns free users into paying customers and reduces churn by adding smart, curated affiliate offers at key user moments. Everyone wins with Encore.Learn more at ⁠https://encorekit.com/*********************************************Ready to take action? Start exploring AppsFlyer's deep linking suite -  coming soon as a standalone solution, independent of their measurement packages → https://bit.ly/46O7Wgd*********************************************Follow us:YouTube: ⁠AppMasters.com/YouTube⁠Instagram: ⁠@App MastersTwitter: ⁠@App MastersTikTok: ⁠@stevepyoung⁠Facebook: ⁠App Masters⁠*********************************************

Klinisch Relevant ist Dein Wissenspartner für das Gesundheitswesen. Drei mal pro Woche, nämlich dienstags, donnerstags und samstags, versorgen wir Dich mit unserem Podcast und liefern Dir Fachwissen für Deine klinische Praxis. Weitere Infos findest Du unter https://klinisch-relevant.de

Nach dem ersten Monument steht der Besenwagen mit offenem Schiebedach schon bereit für die nächsten großen Klassiker im Mutterland des Radsports im Herzen Flanderns. Aus dem offenen Verdeck hat der ehemalige Basketball-Profi Tomas Van Den Spiegeln aus über zwei Metern Höhe alles bestens im Blick. Als Flanders Classics CEO hat Tomas seit dem Opening Weekend Hochsaison. Der Rennveranstalter organisiert u.a. Omloop Het Nieuwsblad, Gent-Wevelgem a.k.a. In Flanders Fields, Dwaars door Vlaanderen und natürlich die Flandern-Rundfahrt.

In this episode, we explore how individualised medicines are evolving from “n=1” treatments (a treatment effective for a single individual) into approaches that could transform care for many people living with rare conditions.  Advances in genomic medicine are making it possible to design highly targeted treatments based on an individual's genetic information. While these therapies may begin as bespoke solutions for a single patient, they can often be adapted, refined or reused to benefit others with similar conditions.  While the research is evolving, the systems needed to deliver these treatments at scale are still catching up. From regulation to access, our guests discuss what needs to change to turn this potential into reality.  Our host Sharon Jones, is joined by:  Ana Lisa Tavares, Clinical Lead for Rare Disease Research at Genomics England  Mel Dixon, Participant Panel member and CEO and Founder of Cure DHDDS  If you enjoyed today's conversation, please like and share wherever you listen to your podcasts.  “However rare your condition is, someone has a right to have hope. Everybody should have a hope that we should be able to find a treatment.” You can download the transcript or read it below. Sharon: What if treatments once designed for just one person could now help many others? Thanks to advances in genomic medicine, regulations are changing and research is expanding. This opens up more options for treatments for rare conditions. But what does this mean and how close is real change? I'm Sharon Jones, and this is Behind the Genes. We look at how genomics is changing healthcare, covering everything from cutting-edge research to real-life stories. Individualised medicines are a fast-moving area, but there's still a big gap between scientific progress and what's actually happening to patients. You could call it the gap between hype and hope. Ana Lisa: However rare your condition is, someone has a right to have hope. Everybody should have a hope that we should be able to find a treatment. Sharon: Coming up, we'll hear from Ana Lisa Tavares, Clinical Lead for Rare Disease Research at Genomics England, and Consultant in Clinical Genetics at Cambridge University Hospital, as well as Mel Dixon, member of the Participant Panel at Genomics England and CEO and founder of Cure DHDDS. Mel opens this chat by explaining why developments in individualised healthcare really matter to her. Mel: This issue is really personal to me. I have three children, two of whom are affected with an ultra-rare DHDDS gene variant, for which there is currently no treatment. Their condition causes symptoms such as, well, it varies between mild to severe learning difficulties, seizures, tremors, and movement and coordination difficulties. But the, the most worrying thing for us was that this condition is actually also progressive. So over time it becomes more of a Parkinsonism and some patients experience dementia-like symptoms and psychosis. So for us to get a treatment that targets the genetic cause of, of their condition is, like, the most important thing in, in our lives. If we could intervene now, they could potentially, at the stage they're at, you know, live an independent life with, with some supports. But if the disease is left to progress, it would be a very different outcome for them. Sharon: I mean, that sounds so difficult and I can't even imagine how life is for you and your family. And I can see what is driving you to find anything to extend the life of your children and to give them that opportunity to, to have a better quality of life. And then Lisa. Ana Lisa: It's a huge burden for families to carry. And I think at the moment there's an additional layer of burden, which shouldn't fall on families, to feel like they need to forge a pathway for their child to have a chance of a treatment. That's, that's a lot to bear. Mel: I think as well, families feel they almost have to become mini scientists in their children's specific condition overnight, because you go to these appointments with the consultants and nobody's heard of the condition and they don't know, they just don't really know what to do with you. So they're asking you, you know, so tell me about this, this gene change. What, what does it do? What does it mean? So you have to become the mini professor in your child's condition to be able to advocate for them. We've had to really learn on our feet so that we're able to advocate and push for research into DHDDS, because without us doing it, nobody else was going to be. Sharon: Yeah. So that's, you know, that's partly what we're here and what this podcast is for, it's here to support families to, to understand this stuff. And Ana Lisa, can you just break it down to us, what is individualised medicines? Ana Lisa: An individualised medicine that's made for one individual person. In reality, sometimes there are other individuals that can also benefit from the same medicines, and sometimes actually, although the medicine is made for one specific person, it might be made using a strategy that other patients could also benefit from, either directly, exactly the same, even, or through tweaking them so that they could work for a different patient. In the context that they're most often referred to at the moment, they're therapies that are being made based on the genetic information about somebody. Sharon: Thank you. I mean, that sounds amazing. And now coming to you, Mel, what does receiving a diagnosis mean for a family? And how do you navigate the space between finally having answers and the reality that the treatment may not yet exist? Mel: So for us, I think, we went down the, the diagnostic route in the hope that we would be able to find a treatment for our children, or there would already be a treatment in place. But unfortunately when we got their diagnosis, we were told that their, their condition was ultra rare, neurodegenerative and also newly discovered. So there was, there was no treatment pathway and actually minimal research happening into it at the time. So it was frustrating, upsetting, um, and it felt like quite a hopeless situation at the start, but actually this was just over three years ago. And through a lot of proactiveness on our part in fundraising, we've been able to better understand the condition and we now have treatments in the pipeline. So in that three-year window, from there being nothing, we now have treatments both in terms of potential drug repurposing candidates and also, um, an individualised therapy called an ASO is also in development for them. So it was hard, but it's given huge benefit to us. Otherwise, we'd just be going, remaining going from specialist to specialist without having any answers or understanding why their symptoms were progressing. Sharon: I mean, that sounds really, really tough and you know, coming back to you, Ana Lisa, could you talk us through how genomics is changing the way we can treat rare conditions? You know, what types of individualised medicines now exist and how do they even work? Ana Lisa: Maybe I'll start with how some of these medicines are working. So with, without going into details, but the sort of principle that these medicines might be able to, to do something called gene editing. So our, our DNA, uh, the instruction manual is made up of genes and it's now can be possible scientifically to change even a single DNA letter code in somebody to try and ameliorate the symptoms of their rare condition. You know that's phenomenal scientific progress to be able to do that. I think a lot of people have heard about gene therapy, where one is trying to get into the body a gene or part of a gene that might be able to sort of replace the function of a gene that isn't working as it should. There are various other strategies. So our DNA is actually used to send messages to our body, if you like, to, to decode these instructions. And so there are medicines that target the next step in this process, the RNA, which are the ASO therapies that Mel was referring to earlier. And really what those are doing are either trying to correct for a protein in our body that isn't working as it should, or to try and get rid of one that shouldn't be there. And so they can act in different ways. And that's actually quite powerful, because you can, theoretically, use these strategies to correct for different genetic rare conditions. So I think going to the sort of first part of your question, maybe if I can phrase it as "directly at source". If you can go upstream and target in a very direct way the cause of a rare condition, then actually you might be able to apply those same principles to many different types of rare condition. We know that there are, you know, 8,000 as a very ballpark number of rare conditions, and it might be that these strategies could be used I don't want to say for all rare conditions, but for many rare conditions where we find the genetic cause, these strategies could collectively be a very powerful way to treat them. And traditionally we've had to understand all the underlying biology, find a druggable target, find a drug that could target that, that's safe, effective, et cetera. And that's a lot of work. And that's still very, very valuable. If we were going to do this for these thousands of conditions, it would probably take us hundreds to thousands of years, collectively. And these strategies provide a lot of hope for being able to do this in a, in a more efficient way, where we can actually use the information used to treat one rare condition and apply those learnings to another rare condition. Sharon : I mean, that's really helpful to understand. So if the science is there, why aren't more patients benefiting from it yet? You know, what's standing in the way from your perspective? Ana Lisa: That's a really good question, and it's complex because the, our whole ecosystem is made up of, of many parts that go from finding a potential strategy that could help a rare condition to a patient benefiting from that. And I think one thing that maybe we haven't touched on yet is the fact that rare conditions can be really rare and affect a really small number of people individually, even though we know collectively they affect so many. You know, in the past it's been easier, if you're taking a condition that's common, that affects thousands of people, it's easier to see and to be sure whether your new medicine is actually working as you think it does and should, and having the benefits that you think. The, the sort of regulators have really clear guidance. We have lots of knowledge about how to assess treatments and have a randomised clinical trial, for example. How the reimbursement process may work in a public healthcare system. And when you, when you, when you sort of set down into the really rare, this is difficult for each stage of the journey. The transformation that's needed is a whole, system-wide transformation to be able to regulate in a scalable, equitable way, these therapies that could actually be an N of one treatment for one individual, that actually maybe one day another individual may also benefit, and sometimes even a group of individuals. It's not just the, the regulator, it's also how do you make it viable. So again, you have to make it scalable, equitable. And even to implement in the NHS down to this very "N equals one" level, and demonstrate that patients could benefit from these treatments, might require sort of fancier ways of assessing these treatments, whether it's statistics, other methodology and I think it's really the system-wide nature that makes this tricky, but is also a fantastic opportunity for, for collaboration, because that, that sort of end goal and benefits could be so, so great. Sharon: Yeah, absolutely. And I mean, Mel, for your side of things, it must sound, you know, quite frustrating where the people in the rare community to not see the support being made more readily available? Mel: Yeah, it is particularly difficult for patients and their families. I think in our case, when you're dealing with a neurodegenerative condition, time is of the essence. So when you know that the science is available or it's ready, but you don't have the systems in place to implement them to the patients so that they can access these much-needed therapies, it's worrying and frustrating. And also I see our children are affected with, with, you know, one of these N of few conditions that there's, you know, there's only 59 confirmed cases of DHDDS worldwide, and we've seen how the system firsthand doesn't fit ultra-rare patients. We can't, when we were looking at drug repurposing, we can't do a traditional clinical trial because we don't have the patient numbers and we don't have the funding. So a placebo-controlled trial just wouldn't be possible for us when there's only, I think, seven confirmed patients in the UK and, um, four that we're actually in, in, in touch with. So it does feel, I think, as Ana Lisa was saying, that we really need a system rethink, um, and refit so that it does start to accommodate these ultra-rare conditions, especially now as there's therapies which are showing huge benefit to patients. Sharon: And so with like all of these challenges, where are you seeing things shift and what does meaningful progress really look like for you? Mel: At the end of last year, the MHRA announced that they were rewriting the regulatory framework for rare conditions, and that fills us with lots of hope for the future. They're recognising that the traditional systems don't work for particularly ultra-rare conditions, and now that we do have these therapies in the pipeline, we, we want to get the patients to be able to access them. And we're also seeing innovation in how evidence is generated and measured. We witnessed this firsthand with our son as he was undergoing baseline tests for his ASO therapy. You know, the use of digital biomarkers, of real-world evidence, how they're increasingly being used for these N of one or N of few populations. And how the individual receiving the treatment becomes their own comparator. So you're not relying on these big natural history studies of the disease or placebo controls. It's you're looking specifically at that individual, getting a really strong baseline and then looking, once they're dosed with the medication, is that improving or stabilising symptoms? So I think this shift in focus is really meaningful for the ultra-rare community and also for them to be part of the decision-making process of what, what benefits do they want from a drug? Like what is meaningful to them? I think there's much more talk about the patients and how the, what will benefit them most. It's not necessarily what the scientists would think or research would think would most benefit, but what, what would make a meaningful difference to the patient? Sharon: I mean, that's good to know because it's kind of putting the person at the centre of, you know, this is what it's all about, isn't it? It's not just the science. We're trying to treat people and it's putting people, people first. Ana Lisa: Just to build on that, it's exactly that, that awareness that is, is growing, I think, that there are so many people affected by a rare condition and, and however rare your condition is, someone has a right to have hope and that the system should be able to cater for many rare conditions, you know, whether they're an ultra-rare or an actually almost common rare condition, everybody should have a hope that we should be able to find a treatment. And it's not a hopeless situation that it's, you know, never going to happen or be too difficult. It's quite powerful, hope. If you can solve for the truly individualised medicine, then you at the same time may also be helping everyone in-between a really common condition and a really rare condition, because right now the system works for common conditions. And if you can take it right down to the sort of radical of, example of an individualised medicine made for one person, then you are also forcing the system to a change for everybody else. And I think that's one of the great benefits of thinking about it as a joined-up system. Sharon: So how do you each navigate between hype versus hope when it comes to rare therapies? Mel? Mel: I like to focus on hope, because when we got our diagnosis, we felt really hopeless and that's a really dark place for a family to be. But as we learnt more about their condition and the rare condition landscape and genomics, we actually learned of all these new therapies that were in the pipeline. We were hearing about, you know, recently, conditions like Huntington's Disease that you never, never previously had any disease-modifying treatment, how they're now being able to be treated with gene therapy with really positive effects. Similarly for other neurodegenerative conditions that have been treated with ASOs, how they're seeing not just disease stabilisation, but improvements. So I know it's, it's still, like, relatively early days with these technologies and therapies, but I think it, it allows families to have hope, which is, which is really, really important, because that statistic, you know, of the, of 95% of rare conditions not having a treatment, it's, it's a really brutal one, uh, to be told at the outset or to learn at the outset. So, you know, if, if these therapies can, can make a huge dent in that, that would be life-changing. It would make a profound difference to many, many families, and I think there's a lot of reason to have hope, taking all of that into consideration. Sharon: And then Lisa? Ana Lisa: I think to work in this area, one needs to be full of hope and optimism because there are so many, um, challenges to overcome as a community. Uh, but I think that means that people are also incredibly collaborative, because they know that we need to work together for this to succeed. And no one, you know, one individual, one organisation can do it on their own. It truly has to be a crosscutting, collaborative endeavour. The fact that we, in the UK, have resources like the National Healthcare System,Genomics England in partnership with the NHS runs a National Genomic Research Library. And so the fact that you could look at, at tens of thousands of, of genomes for many, many individuals with rare conditions. That gives me hope because it means that if a treatment is made for another person, it could be in a different country in the world, and if we could find another patient, it doesn't matter what specialty they're under, where they are, we should be able to find them and connect with their clinical team if, you know, if they've consented for the National Genomic Research Library. And so to me, that feels, that whilst there's, there is a lot of hype in the sense that some of the really well-publicised cases, really had a lot of people working on them and a lot of resources to make it happen. But that gives hope to everybody else that follows that actually it is doable and if we can make better systems, and having these national resources that we do, the fact that, there are a lot of guidelines being written at the moment, both international and national. And again, they show that the sort of scaffolding is starting to be in place to apply these in an equitable scalable way. It might not be that you're so much looking for a specific rare condition as for a particular type of genetic variant that could be targeted in the same strategic way, and that therefore you could look across many different rare conditions. So again, all these sort of pieces of the puzzle are, are filling me with, with, with hope. Sharon: You touched upon, um, inequity there. Now, you know, is there a risk of inequity given what we've talked about in terms of those challenges? Ana Lisa: I think we, we always have to have the lens of equity in everything we, we do. And that, and that really does apply to healthcare and, and in fact, probably the whole rare disease community are, are, are not well served in terms of therapies at the moment. There are so few, um, therapeutic options and so I think there's a massive inequity in that this, our systems are not geared, uh, towards rare conditions. I suppose, you know, different countries have different healthcare systems and some of the sort of first personalised therapies may require a lot of money behind them to, to happen, but they will be pioneers in leading the way for how this can be done. And I think in the UK we have a lot of the infrastructure and the, a sort of a strong, that's very equitable, I think. And so we could do this in a, in a much more open and equitable way. Sharon: Mel? Mel: Cost is always, unfortunately, and it, when it's your family that's affected you, you know, you hate the thought that things are coming down to cost and, and money. But I, I think as Ana Lisa said, if, if the system absorbs the initial cost. You know, it seems that those longer-term costs could come down significantly. We already see with our very small DHDDS community that an ASO, which is an allele specific that was made personally for one, for one child, can actually also benefit my son, even though they have a different variant. So if the cost of the ASO is 1.2 million per person, but if you suddenly find actually one other person can share that, that's almost halving the, the cost. And then if then you're finding out that actually, oh no, 3, 4, 5, 10 people can all have that same ASO, suddenly it becomes much more cost-effective and more sustainable. So I think, as we have to think about cost, I think that also allows us to have more hope that these therapies can, the cost of these therapies that are obviously hugely expensive at the moment, can be brought down in the longer term. Ana Lisa: There are a lot of things that people want to do in the NHS. People can be working under quite hard circumstances, so to talk about making a therapy for one individual can be difficult and people can sometimes, I think, think that it's a pie-in-the-sky conversation. However, I think that, you know, all the clinicians I know who work with families with rare conditions, what they'd most like to be able to do is to be able to offer a therapy. And so I think a lot of people see this as a, as a big opportunity, despite these initial hurdles. One thing I often think about is my grandfather, when he was alive, every phone conversation, he would start with, "How many lives have you saved today?" And so I think that's the, that's our challenge. Sharon: Wow. That's, that's really powerful. Mel: Just echoing really what Ana Lisa was saying, I feel the, um, inequity lies in rare conditions as a, as a whole, from the point of diagnosis to the lack of pathway, um, to, to the lack of system in place for them. You wouldn't have a patient with a life-changing cancer diagnosis receive that information in a telephone call, and that is the stark reality for many rare disease patients. That's how they receive the, that's how they often receive the news. That was certainly our, our experience. And, and from that point, there was then no pathway. It's just this horrendous feeling of isolation. And I think now that there are these treatments in place and therapies in, in place, it's about time we change that because often the rare, the rare condition community, and certainly those with ultra-rare conditions as well, they're probably like some of the most underserved members of the community in that it's their parents and their families that have to advocate. Otherwise, without that, they, they often wouldn't stand a chance of understanding the disease, let alone finding a treatment. So I think the whole system needs to have a reset, to think about these rare condition patients and, put them at the heart as they do for more common conditions. Ana Lisa : I completely agree. And you mentioned cancer, and there are actually quite a few parallels. So there might be really common cancers that affect a lot of people that are being, uh, subsetted down into different groups depending on the genetics that are related to that particular cancer and therefore what treatments might be most effective. And so I think there's, there's a lot we can each learn from each other between the rare disease and cancer communities. Perhaps as in rare disease we scale up to apply the same strategies to many different rare conditions and patients. Even if they're being tweaked for their particular genetic variant and cancer, sometimes one is subsetting down to treat specifically that, exactly that cancer subtype. So there's a lot we can learn and I completely agree that the, the rare disease community deserves the same chance at at treatments, and the hope that that comes with. Sharon: Thank you. It feels like there needs to be some kind of seismic system change along with this piece around collaboration and how, you know, the science is there, but it's how do we bring it to families who are facing these difficulties with it, you know, their children and, and rare conditions. We'll wrap it up there. Thank you to our guests, Ana Lisa Tavares and Mel Dixon, for joining me as we discussed the evolving landscape of individualised medicines. And thank you for listening. If you'd like to hear more like this, please subscribe on your favorite podcast app. Behind the Genes is produced by Deanna Barac, Florence Cornish, Sophie McLachlan and Patrick Wallace at Bespoken Media.  

Want to convert more free users into paying customers?In this video, Steve P. Young shares little-known app monetization strategies used by top subscription apps to increase conversions, improve paywalls, and grow revenue.If you're building a mobile app, SaaS product, or subscription app, these monetization tactics can dramatically improve your trial conversions, paid subscribers, and overall revenue.You'll learn:✅ 3-Screen Paywalls that increase subscription conversions✅ Trial-to-Discount Strategy to convert hesitant users✅ Paid Intro Offers that outperform free trials✅ Reverse Trials that turn free users into paying subscribers✅ Pay-What-You-Want Pricing to increase purchase conversionsIf you're struggling with low trial conversion, weak paywalls, or too many free users, these tactics can help you unlock new revenue from your existing user base.Want access to the full video course? Join 100+ app founders sharing what's working in app growth, app marketing, and monetization strategies:https://appfounders.coWatch - How a Solo Founder Built a $30K/Month App with 5.2M Installs:https://youtube.com/live/jN6e9sSyaoo?feature=shareYou can also watch this video here: https://youtu.be/FWF_AbsR0qc*********************************************SPONSORSStill designing, resizing, and uploading screenshots manually? AppScreens lets you pick from hundreds of high-converting templates, generate for every device size and language in minutes, and upload automatically to directly to App Store Connect and Google Play Console. Trusted by more than 100K developers and ASO experts worldwide.Try it free: https://appscreens.com/?via=am*********************************************Thinking about your next great app? This is the best time to make it! Contact Chaim at b7dev.com and get your idea started! Delivery times are super short; you'll be surprised by the cost to develop! B7dev.com*********************************************Ready to take action? Start exploring AppsFlyer's deep linking suite -  coming soon as a standalone solution, independent of their measurement packages → ⁠https://bit.ly/46O7Wgd*********************************************Follow us:YouTube: ⁠AppMasters.com/YouTube⁠Instagram: ⁠@App MastersTwitter: ⁠@App MastersTikTok: ⁠@stevepyoung⁠Facebook: ⁠App Masters⁠*********************************************

On this episode, Pete and Julie welcome Matt Vaadi, longtime payroll industry exec, CEO of GuHRoo, and host of The Payrollin' Podcast, to take the pulse on the small businesses buyer and talk about the realities of the marketplace for SMB HR and payroll solutions.  From tech-first vs service-first buyers to the rise of niche payroll providers, Matt offers an insider's view of how small and mid-sized businesses are buying, switching, and scaling HR and payroll today. The conversation explores why overcrowding in the HCM and payroll market is reshaping go-to-market strategies, why centers of influence like CPAs, brokers, and consultants are more powerful than ever, and how private equity and consolidation are quietly redefining PEO and ASO models. The group also digs into the future of embedded payroll, AI-driven automation, and why many SMB buyers are demanding API-driven, workflow-centric platforms instead of traditional systems. Matt shares how specialization is driving higher growth and valuations, and what HR tech and payroll vendors must do to stay competitive in a market where trust, simplicity, and integration now matter more than brand. Connect with Matt: LinkedIn: https://www.linkedin.com/in/mattvaadi/  https://www.guhroo.co/   https://www.payrollinpodcast.com/  Connect with the show: LinkedIn:  http://linkedin.com/company/hr-payroll-2-0 X: @HRPayroll2_0  X: @PeteTiliakos  X: @JulieFer_HR BlueSky: @hrpayroll2o.bsky.social YouTube: https://www.youtube.com/@HRPAYROLL2_0  WRKDefined Podcast Network: https://wrkdefined.com/podcast/hr-payroll-20  Thank you to our marquee sponsors for powering the HR & Payroll 2.0 podcast forward!  G-P ‘Globalization Partners': https://www.globalization-partners.com/ OneSource Virtual: https://hubs.ly/Q03YFNR90 Zoho: https://www.zoho.com/press.html Thank you to our ‘wizard behind the curtain' and show producer Ryan Kielma: https://www.linkedin.com/in/ryan-kielma/

Fini les bouteilles et les gobelets au Marathon de Paris ! Place aux points d'eau et aux flasques… sauf pour une poignée de privilégiés. À la suite d'une polémique, ASO a décidé d'étendre le service de bidons aux coureurs engagés sur un chrono sous les 2h50, soit moins de 4' au kilomètre. Pourquoi cette limite ? Comment gérer la frustration de ceux qui seront juste au‑dessus ? Que risque un coureur qui jette son bidon n'importe où ? Dans cet épisode, Thomas Delpeuch, directeur de course du Marathon de Paris, répond à toutes les critiques et explique les coulisses de cette révolution de l'hydratation, entre contraintes écologiques, sécurité et performance. 

Most founders quit after their first failed product. Vadim failed three apps before finally building one that worked.Vadim is the founder of KBMH, a kettlebell workouts app that grew from a simple MVP built for himself into a fast-growing fitness app generating $80K+ per month.After years of failed ideas, bad product decisions, and zero traction, everything changed when Vadim focused on validating ideas faster, testing onboarding and monetization aggressively, and building a personal brand that now reaches 400K+ followers on social media.In this episode, Vadim shares the real story behind the growth of KBMH, from launching fast with landing pages to running nonstop monetization experiments and even how a mistake in his cancellation flow generated a $40K revenue spike.If you're building an app, validating a new idea, or trying to scale revenue, this conversation is packed with real lessons from the trenches.You will discover:✅ The landing page strategy he uses to validate app ideas before building✅ Onboarding and monetization experiments that drove 15% trial-to-paid conversion✅ The accidental $40K revenue spike caused by a cancellation flow mistake✅ Why simple ad creatives outperform polished adsLearn More:Explore the KBMH Apphttps://kbmh.app Follow Vadim on Instagramhttps://www.instagram.com/vadim.kettlebell/You can also watch this video here: https://youtube.com/live/eZGIcL-IvWY*********************************************SPONSORSStill designing, resizing, and uploading screenshots manually? AppScreens lets you pick from hundreds of high-converting templates, generate for every device size and language in minutes, and upload automatically to directly to App Store Connect and Google Play Console. Trusted by more than 100K developers and ASO experts worldwide.Try it free: https://appscreens.com/?via=am*********************************************Want to know what ads your competitors are running right now?SocialPeta gives you access to real ad creatives and market insights across apps, games, and emerging content formats, so you can stay ahead without endless trial and error.Check it out at https://www.socialpeta.com/*********************************************Ready to take action? Start exploring AppsFlyer's deep linking suite -  coming soon as a standalone solution, independent of their measurement packages → ⁠https://bit.ly/46O7Wgd*********************************************Follow us:YouTube: ⁠AppMasters.com/YouTube⁠Instagram: ⁠@App MastersTwitter: ⁠@App MastersTikTok: ⁠@stevepyoung⁠Facebook: ⁠App Masters⁠*********************************************

App Store Connect shows a lot of data, but it's not always easy to understand.In this video, Steve P. Young demos AppSignals, a new app analytics dashboard built specifically for indie app developers and small app teams.AppSignals simplifies your App Store analytics and shows the most important app growth metrics in one clear dashboard.Instead of digging through complicated reports, you can instantly see some important app metrics. If you're building or scaling an app and want a clear view of your installs, conversions, and revenue, this tool is designed to make app analytics much easier.Try it here

In this episode, we break down the 2026 State of Subscription Apps report from RevenueCat, one of the largest analyses of subscription app performance ever conducted.We're joined by David Barnard, Growth Advocate at RevenueCat, to unpack the key insights from the report.The study analyzes 75,000+ apps and more than $11B in revenue across over a billion transactions, revealing what's actually working in today's subscription economy.One of the most surprising findings: apps launched before 2020 still generate nearly 70% of all subscription revenue, even though thousands of new apps are launched every month.If you're building or growing a subscription app, these benchmarks will help you understand where you stand and which levers can truly move revenue. You will discover:✅ Why the top 25% of apps grew 80%+ while the bottom quartile shrank✅ Why hard paywalls convert 5× better than freemium✅ The surprising truth about AI apps: higher revenue but worse retention✅ The growing importance of web-to-app funnels and web revenue✅ Benchmark metrics like conversion rates, RPI, and retentionLearn More:Connect with David:https://www.linkedin.com/in/drbarnard/State of Subscription Apps 2026:https://www.revenuecat.com/state-of-subscription-apps/?utm_source=appmasters&utm_medium=youtubeYou can also watch this video here: ⁠⁠https://youtube.com/live/8Tk_EHQUeaY*********************************************SPONSORSStill designing, resizing, and uploading screenshots manually? AppScreens lets you pick from hundreds of high-converting templates, generate for every device size and language in minutes, and upload automatically to directly to App Store Connect and Google Play Console. Trusted by more than 100K developers and ASO experts worldwide.Try it free: https://appscreens.com/?via=am*********************************************Got tons of freemium users who won't upgrade? Encore turns free users into paying customers and reduces churn by adding smart, curated affiliate offers at key user moments. Everyone wins with Encore.Learn more at ⁠https://encorekit.com/*********************************************Ready to take action? Start exploring AppsFlyer's deep linking suite -  coming soon as a standalone solution, independent of their measurement packages → https://bit.ly/46O7Wgd*********************************************Follow us:YouTube: ⁠AppMasters.com/YouTube⁠Instagram: ⁠@App MastersTwitter: ⁠@App MastersTikTok: ⁠@stevepyoung⁠Facebook: ⁠App Masters⁠*********************************************

I le kuata i le 3 i le aoauli o le Aso 11 o Mati 2011, na to ai se mafui'e na fuaina i le 9 le malosi i le fua mafui'e i le gataifale i Matu i Sasa'e o le motu o Honshu i Iapani.

Na fa'amanatuina i le Aso ua tuana'i (Aso 8 o Mati) le Aso Fa'avāomālō o Tinā ma Tamaita'i, le International Womens Day.

In this episode, we are joined by Zakhar Azatian, a bootstrapped technical solo founder based in San Francisco and the creator of BeHard, a gamified accountability app built around lifestyle challenges.He's a two-time founder with one successful exit and has grown B2C mobile products to over 1 million users, without a big team or massive funding.In this session, Zakhar breaks down how he generates and tests hundreds of ad creatives per month, the gamification mechanics that dramatically increased retention and referrals, and how he treats App Store search like a technical optimization problem, not just marketing.If you're building a consumer app and want practical growth tactics, this episode is packed with real execution frameworks.You will discover:✅ How to generate and test hundreds of ad creatives per month with a tiny team✅ How to treat App Store search like a code optimization problem✅ Paid growth insights from Meta, TikTok & influencer marketing Learn More:Explore Be Hard

How do you successfully sell your app, prepare for a business exit, or structure a SaaS acquisition deal? In this episode, Steve P. Young, Founder of App Masters, on Exit Podcast by Flippa, shares real-world lessons from building, selling, and nearly exiting multiple app businesses, plus what founders must know before attempting a 7-figure exit.You'll learn:✅ How to sell apps on Flippa✅ Common mistakes founders make during exits✅ When it's the right time to sell your startup✅ Why distribution matters more than productSteve also explains how he scaled App Masters from a side hustle into a 30+ person global team, and why he shifted from selling businesses to acquiring them.If you're a startup founder, SaaS operator, app developer, or entrepreneur thinking about selling your company, this episode breaks down the exit process step by step.

Search inside the app stores is changing — and AI is accelerating that shift. In this episode, we speak with Dave Bell, CEO at Gummicube, about how artificial intelligence is transforming the way users discover apps. Dave explains why search is becoming more conversational and intent-driven, how natural language queries are reshaping rankings, and why the era of optimizing for a single dominant keyword is fading. As users ask longer, more specific questions — both inside the App Store and through tools like ChatGPT — ASO strategies must evolve to reflect how people actually search. If you're responsible for app visibility, organic growth, or ASO strategy, this episode offers a timely look at where search is heading next. Without any further ado, let's get started. Today's topics include: How AI is changing app store search behavior Natural language queries and intent-based ranking Why single-keyword optimization no longer works The growing role of LLMs in app discovery Apple opening the App Store to web indexing What AI-driven search means for future ASO strategy Links and Resources: Dave Bell on LinkedIn Gummicube Business Of Apps - connecting the app industry Quotes from Dave Bell “It's not about looking for the one keyword to rule them all. It's not The Lord of the Rings — it's about understanding all the ways users might search and find your app.” “Users are really being retrained both in the way that they search for information and in terms of what results they expect from a natural search.” “LM models are now including summaries and links to apps that best fit a user's prompt, giving users a new path into the app stores.” Host Business Of Apps - connecting the app industry since 2012

In this solo episode, Steve P. Young, Founder of App Masters, breaks down the newest and most effective app monetization strategies working right now and some key insights he presented at AppsFlyer's MAMA San Francisco 2026.With competition increasing across the App Store and Google Play, monetization is no longer just about adding a paywall; it's about designing the right pricing strategy, structuring trials intelligently, and optimizing every step of the user journey.Steve will share real examples from top-grossing apps and explain how leading subscription apps are increasing revenue without increasing downloads.This session is perfect for founders, product managers, and growth teams looking to improve conversions and maximize subscriber lifetime value.You'll Learn:✅ How top apps structure paywalls to increase conversions✅ The smartest way to use trial-to-discount and paid intro offers✅ How to recover lost revenue with winback and triggered discount strategies✅ Pricing psychology tactics that increase ARPU without hurting conversionLearn More:Subscribe to the newsletter and get free access to the App Growth Playbook:https://appmasters.com/appgrowth-playbook/ You can also watch this video here: https://youtube.com/live/m-1TYFoA2sU*********************************************SPONSORSStill designing, resizing, and uploading screenshots manually? AppScreens lets you pick from hundreds of high-converting templates, generate for every device size and language in minutes, and upload automatically to directly to App Store Connect and Google Play Console. Trusted by more than 100K developers and ASO experts worldwide.Try it free: https://appscreens.com/?via=am*********************************************Thinking about your next great app? This is the best time to make it! Contact Chaim at b7dev.com and get your idea started! Delivery times are super short; you'll be surprised by the cost to develop! B7dev.com*********************************************If you're advertising your growing mobile app, you need a measurement partner you can actually rely on — and that's where AppsFlyer comes in.It gives you a clear view of your entire funnel — from the first impression all the way to the install, in-app events, and user LTV. You'll know what's driving real results, and what's just noise.What teams love about it? It's stable, accurate, and built to handle everything the mobile world throws at you — privacy changes, creative optimization, you name it.And when you need help? Their global support team is there 24/7 — not just to fix things, but to help you grow.If you're ready to level up your mobile marketing and make smarter decisions, check out AppsFlyer.com *********************************************Follow us:YouTube: ⁠AppMasters.com/YouTube⁠Instagram: ⁠@App MastersTwitter: ⁠@App MastersTikTok: ⁠@stevepyoung⁠Facebook: ⁠App Masters⁠*********************************************

With AI tools making it easier than ever to launch new apps, competition is exploding. The real competitive advantage today isn't product — it's distribution.In this video, I break down the single most important factor in app marketing: channel market fit and the 5 distribution channels you should consider to grow your app faster.If you're struggling to get downloads, this is the uncomfortable truth about app marketing in 2026.You'll Learn:✅ The #1 mistake founders make in app marketing✅ Why distribution beats product in 2026✅ How to use ASO for organic growth✅ Why Apple Ads is the best starting point✅ The “get the refund” mindset for growth✅ A controversial lifetime free growth hack (that still works)

In this episode, we are again joined by Michael Gants, founder and CEO of Encore, a new SDK helping subscription app developers turn churned users into paying subscribers.Michael is a Stanford grad, a Time Magazine “Leader of Tomorrow”, and a seasoned founder with a passion for building sustainable consumer businesses. Michael breaks down how leading apps use lifecycle experimentation, not just acquisition, but to retain and to winback. We'll go deep into A/B testing across the user journey, smart winback strategies, and the systems top teams use to improve retention, conversions, and subscriber value without relying on more installs.If you're building or scaling a subscription app, this session will help you think beyond surface-level experiments and focus on what actually moves revenue.You will discover:✅ What lifecycle experiments every subscription app should be running✅ How to structure A/B tests beyond onboarding and paywalls✅ Proven winback strategies that actually bring subscribers back✅ How smart layers and options increase subscriber conversionLearn More:Explore Encorehttps://encorekit.com/You can also watch this video here: https://youtube.com/live/x-JmAZbnD9M⁠⁠*********************************************SPONSORSStill designing, resizing, and uploading screenshots manually? AppScreens lets you pick from hundreds of high-converting templates, generate for every device size and language in minutes, and upload automatically to directly to App Store Connect and Google Play Console. Trusted by more than 100K developers and ASO experts worldwide.Try it free: https://appscreens.com/?via=am*********************************************Thinking about your next great app? This is the best time to make it! Contact Chaim at b7dev.com and get your idea started! Delivery times are super short; you'll be surprised by the cost to develop! B7dev.com*********************************************If you're advertising your growing mobile app, you need a measurement partner you can actually rely on — and that's where AppsFlyer comes in.It gives you a clear view of your entire funnel — from the first impression all the way to the install, in-app events, and user LTV. You'll know what's driving real results, and what's just noise.What teams love about it? It's stable, accurate, and built to handle everything the mobile world throws at you — privacy changes, creative optimization, you name it.And when you need help? Their global support team is there 24/7 — not just to fix things, but to help you grow.If you're ready to level up your mobile marketing and make smarter decisions, check out AppsFlyer.com *********************************************Follow us:YouTube: ⁠AppMasters.com/YouTube⁠Instagram: ⁠@App MastersTwitter: ⁠@App MastersTikTok: ⁠@stevepyoung⁠Facebook: ⁠App Masters⁠*********************************************

On this episode of Astonishing Healthcare, Judi Health's Mike Tate (VP, National Business Development) and Mark Pearce (Director, TPA Operations) join us in the studio to discuss the role of Third-Party Administrators (TPAs) in the self-funded employer market. As Mike explains, TPAs act as the "enforcers" of an employer's plan document, responsible for pulling everything together and ensuring claims accuracy, network access, and financial stewardship. Mark dives into the distinction between carrier-owned (ASO) and independent TPAs, explaining how independent models offer greater flexibility in plan design. And of course, they highlight a significant industry challenge: legacy technology. Many administrators rely on antiquated systems that limit customization and data visibility. In contrast, modern platforms empower plan sponsors to integrate point solutions effectively, customize networks for high-value care (e.g., through centers of excellence), and drive better member engagement. If you've ever asked yourself, "What does a TPA really do?" or "Should I look at different TPAs?" this episode will be worth your time to listen to.Ultimately, successful healthcare administration relies on managing "hundreds of little things" correctly for each benefit (Rx, medical, vision, and dental) - from provider payments to member support. That's how you create positive financial and clinical outcomes. Related ContentAH080 - Health Benefits 101: The Importance of "Smart" Care Navigation, with Andy KageleiryReplay: The Future of Health Benefit Design: How Judi® Powers Seamless Care and Better OutcomesAH067 - Aligned Health Benefits and the Freedom to Unbundle, with Kristin Begley, PharmDJudi Health™ Earns Best Healthcare InsurTech Solution in the 9th Annual MedTech Breakthrough Awards ProgramFor more information about Judi Health and this episode, please visit Judi Health - Insights.

O le masina nei (Aso 14 Fepuari) na atoa tonu iai le 60 tausaga o Tupe Tesimale i Ausetalia.

Want to increase your organic downloads without spending money on ads? In this video, I break down our proven app store optimization (ASO) framework for 2026. Whether you are an indie developer or managing a big brand, these strategies will help you rank higher on both the Apple App Store and Google Play Store.We cover the exact steps we use at App Masters to help clients find success, from keyword research to conversion rate optimization.In this ASO tutorial, you will learn:✅ The most important ASO ranking factors in 2026✅ How to find low-competition keywords that still drive revenue✅ The do's and dont's of selecting keywords✅ Some Real Case Studies:- $1,600 in revenue in the first 22 days from organic search- $3,000/month purely from long-tail ASO strategy- 90+ #1 keyword rankings using low-traffic terms

AI has fundamentally changed app development. With vibe coding, agentic workflows, and modern AI development tools, what used to take 6 months to build can now be shipped in weeks. Costs are lower than ever. Speed is no longer the bottleneck.But here's the problem: faster development hasn't led to better products or stronger app businesses.In this livestream, we're joined by Chaim Sajnovsky, Founder of B7 Dev, a development studio that has helped startups go from idea to launch for over a decade.Chaim brings real-world experience helping founders navigate AI-powered app development, outsourced development teams, and early-stage decision-making. Together, we'll break down why planning, positioning, and distribution now matter more than code, and why so many founders still fail even when building faster than ever.You will discover:✅ How AI reduced app development time and cost by 80%✅ Why “what to build” is now more important than “how to build.”✅ How to define your main hypothesis before writing code✅ Why most of these features don't drive product-market fit✅ AI tools founders are using right now (including Claude Code)Learn More:https://www.linkedin.com/in/chaim-sajnovsky-5003494/http://www.b7dev.com/You can also watch this video here: ⁠⁠https://youtube.com/live/unb8p-5MkuA*********************************************SPONSORSStill designing, resizing, and uploading screenshots manually? AppScreens lets you pick from hundreds of high-converting templates, generate for every device size and language in minutes, and upload automatically to directly to App Store Connect and Google Play Console. Trusted by more than 100K developers and ASO experts worldwide.Try it free: https://appscreens.com/?via=am*********************************************Got tons of freemium users who won't upgrade? Encore turns free users into paying customers and reduces churn by adding smart, curated affiliate offers at key user moments. Everyone wins with Encore.Learn more at ⁠https://encorekit.com/*********************************************If you're advertising your growing mobile app, you need a measurement partner you can actually rely on — and that's where AppsFlyer comes in.It gives you a clear view of your entire funnel — from the first impression all the way to the install, in-app events, and user LTV. You'll know what's driving real results, and what's just noise.What teams love about it? It's stable, accurate, and built to handle everything the mobile world throws at you — privacy changes, creative optimization, you name it.And when you need help? Their global support team is there 24/7 — not just to fix things, but to help you grow.If you're ready to level up your mobile marketing and make smarter decisions, check out AppsFlyer.com *********************************************Follow us:YouTube: ⁠AppMasters.com/YouTube⁠Instagram: ⁠@App MastersTwitter: ⁠@App MastersTikTok: ⁠@stevepyoung⁠Facebook: ⁠App Masters⁠*********************************************

Most AI photo apps try to do everything, and end up blending in.In this video, Steve P. Young breaks down how Photo Revive AI scaled to over $500K/month by doing the opposite: niching down first, then expanding later.Instead of launching as “another AI image generator,” this app positioned itself around photo restoration and revival and used smart ASO, onboarding, and paywall strategies to win in a brutally competitive market.You'll learn:✅ Why niching down beats competing in red-hot AI categories✅ How Photo Revive AI generates ~$500K/month (verified across multiple tools)✅ The exact onboarding and paywall flow driving conversions✅ How credit-based pricing controls AI costs and boosts revenue✅ Why distribution matters more than features or UISteve walks through:• Real revenue estimates from Sensor Tower, AppFigures, and AppMagic• The full user journey from install → upgrade• Paywall tactics most founders overlook• How to start a niche, win early traction, and expand laterIf you're building:

In this episode, we're joined by Ben Moore, U.S. Managing Director of BeReal, one of the most culturally relevant social apps of the past decade.With 41M+ monthly active users worldwide, BeReal became App of the Year 2022 by doing what most social platforms wouldn't: going against algorithms, filters, and AI-driven content.With a background leading growth and monetization at TikTok, Walmart Connect, and global media networks, Ben brings a rare inside perspective on what actually drives product-market fit, retention, and cultural relevance in consumer apps.If you're building a consumer app and struggling with retention, differentiation, or product-market fit, this conversation will challenge conventional growth advice and give you a clearer playbook for what actually works in 2026 and beyond.You will discover:✅ How BeReal scaled to 41M MAU by removing algorithms instead of optimizing for them✅ Creator-led growth in 2026 and beyond✅ Lessons from BeReal's journey: from viral hype → durable, loyal product✅ Practical lessons app founders can apply to build durable growth in saturated marketsLearn More:

With the racing hotting up all over the pro cycling world, we return with the same Friebe-Birnie-Hatch trio as last week to review the latest action and talking points. The biggest news story of the week was ASO's decision to hand Spanish outfit Caja Rural a Tour de France wild card at the expense of the Unibet Rose Rockets. We discuss to what extent Caja's place on the startline in Barcelona is justified and the case for the opposition i.e. the Rockets.One man who'll certainly be heading to the Tour, barring accident, is Remco Evenepoel. His three wins in his first three outings for Red Bull-BORA-hansgrohe in Mallora augur well for the rest of season. Daniel's question is: could Remco even be the man to ruin Tadej Pogačar's Sanremo dream?Another candidate for that role, of course, is Mathieu van der Poel. He won his eighth world cyclocross title at the weekend, which has us wondering about the Winter Olympics extending his career in the discipline.EPISODE SPONSORSIndeedIf you are looking to hire someone for your company, maybe the best way isn't to search for a candidate but to match with Indeed. Go to indeed.com/cycle now to get a £100 sponsored job credit and get matched with the perfect candidate fast.BikmoThis episode of The Cycling Podcast is brought to you by Bikmo cycle insurance – because let's face it, things happen. Whether it's a crash landing, the heartbreak of a stolen bike, or the ultimate facepalm moment of reversing over your prized aero wheel, Bikmo has you covered. Flexible policies that you can cancel anytime, 50% off extra bikes in your household, protection for your kit, race entries, and even damage while travelling to your next epic ride – they've thought of it all. Protect your ride before it's too late – head to Bikmo.com to get covered.BabbelLearn a language the fun, easy way with intuitive 15-minute lessons you can do when you want. Choose from 14 languages including Spanish, French, Italian and German. Listeners can get up to 60% off for a limited time only at babbel.com/cycleFollow us on social media:Twitter @cycling_podcastInstagram @thecyclingpodcastFriends of the PodcastSign up as a Friend of the Podcast at thecyclingpodcast.com to listen to new special episodes every month plus a back catalogue of more than 300 exclusive episodes.The 11.01 CappuccinoOur regular email newsletter is now on Substack. Subscribe here for frothy, full-fat updates to enjoy any time (as long as it's after 11am).The Cannibal & BadgerFriends of the Podcast can join the discussion at our new virtual pub, The Cannibal & Badger. A friendly forum to talk about cycling and the podcast. Log in to your Friends of the Podcast account to join in.The Cycling Podcast is on StravaThe Cycling Podcast was founded in 2013 by Richard Moore, Daniel Friebe and Lionel Birnie.

AppAdvice has officially shut down — so what does that mean for Apps Gone Free campaigns and lifetime free promos?In this video, Steve breaks down what really happened, why Apple is paying closer attention to these campaigns, and whether Apps Gone Free strategies still work in 2026.He'll share real data, real case studies, and hard-earned lessons from running these campaigns for years, including what triggered Apple's crackdown, what mistakes to avoid, and how app founders can still use promotions to kickstart downloads without risking app rejection or review removals.If you're struggling with app discoverability, ASO, or early traction, this video will help you understand the dos and don'ts of Apps Gone Free campaigns in today's crowded App Store.You'll learn:✅ Why AppAdvice shut down and what it means for app marketing✅ Real case studies showing 2,000–6,000 downloads in days (post-AppAdvice)✅How Apps Gone Free campaigns can still boost ASO and organic installs✅ The right and wrong way to ask for App Store reviews✅ How Indie App Santa fits into the future of app distributionKey takeaway:Apps Gone Free campaigns aren't dead, but the rules have changed. If you run them the wrong way, you risk Apple intervention. If you run them the right way, they can still be one of the fastest ways to jumpstart app growth.

In this episode, we're joined by Liubomyr Pivtorak, Chief Product Officer at Hily, one of the world's fastest-growing dating apps with over 40 million users worldwide.Liubomyr has spent the last 10 years in B2C mobile, including 8 years in the hyper-competitive dating industry, leading products that scaled to 10M+ and 30M+ users globally.He'll take us behind the scenes of how Hily grew in a red ocean market, competing against giants like Tinder, Hinge, and Bumble — by running 100+ in-app experiments every quarter and obsessing over data, user behavior, and retention.You will discover:✅ The experiment-driven framework that powers Hily's growth (100+ experiments every quarter)✅ How to grow in a red ocean market like dating apps✅ What actually worked vs what failed — real growth experiment stories✅ The data-driven mindset behind scaling from millions to tens of millions of users✅ How to compete with giants like Hinge, Bumble, and Tinder using smarter experimentsLearn More:Try Hily → https://hily.com Connect with Liubomyr → https://www.linkedin.com/in/liubomyrp/You can also watch this video here: ⁠⁠https://youtube.com/live/rUiISNtS3ssGet training, coaching, and community: https://appmasters.com/academy/*********************************************SPONSORSGot tons of freemium users who won't upgrade? Encore turns free users into paying customers and reduces churn by adding smart, curated affiliate offers at key user moments. Everyone wins with Encore.Learn more at https://encorekit.com/*********************************************Still designing, resizing, and uploading screenshots manually? AppScreens lets you pick from hundreds of high-converting templates, generate for every device size and language in minutes, and upload automatically to directly to App Store Connect and Google Play Console. Trusted by more than 100K developers and ASO experts worldwide.Try it free: https://appscreens.com/?via=am*********************************************Follow us:YouTube: ⁠AppMasters.com/YouTube⁠Instagram: ⁠@App MastersTwitter: ⁠@App MastersTikTok: ⁠@stevepyoung⁠Facebook: ⁠App Masters⁠*********************************************

Luke Rosen was working as an actor and writer in New York when his daughter Susannah was diagnosed with KIF1A, an ultra-rare neurodegenerative condition. It's often fatal. At the time they received Susannah's diagnosis, Luke and his wife Sally didn't have much hope. There was no treatment for KIF1A, and there wasn't much work being done on it among researchers. But Luke, one of the most optimistic people you'll ever meet, did what so many parents of children with rare diseases do...he threw himself at the problem. He and Sally started the KIF1A.org Foundation so they could start building research that could go towards finding a treatment for their daughter.  It was the beginning of a long journey for the family. Ultimately, that journey led them to the n-Lorem Foundation, an organization founded by CNBC Cures Advisory Board member Dr. Stan Crooke that offers free ASO treatments to individuals with nano-rare diseases. Thirty years in the making, Antisense oligonucleotide (ASO) technology bridges genomic discovery to personalized medicine one patient at a time. Because of the work done by n-Lorem, Susannah is now receiving treatment for her KIF1A. Luke says the treatments helped for while, though he's now worried the disease is catching up.For more about Susannah's story: visit: https://www.kif1a.org/n-lorem's work is here: https://www.nlorem.org/ Join us in advancing awareness and understanding of rare diseases. Visit CNBC.com/Cures to access clips, resources, or to sign up for our weekly newsletter.  Follow Becky Quick on X: @BeckyQuickPlease share your thoughts or rare disease story in the comments, and join us on The Path. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Most app founders overcomplicate things. This Notepad app? It makes $20,000/month with a design straight out of 2013.

In this episode, we're joined by one of our community members, John McEvoy, founder of Momego, the worldwide transit tracking app with over 5.2 million installs and 400,000 daily active users, built entirely by one person.John started as a graphic designer and taught himself to code. Today, his app generates $30K in monthly recurring revenue, powered by localized ASO, clever ASA, and great features.He'll share his exact frameworks for growth, from keyword localisation to subscription retention, all based on real results from running a successful utility app in a competitive market.You will discover:✅ How localised ASO helped Momego reach 5M+ installs✅ The Apple Search Ads strategy John uses to scale profitably✅ How to test app icons, pricing, and onboarding flows that convert✅ Why reverse trials outperform free trials for mobile apps✅ The features that keep users paying (widgets + live activities)Learn More:

If you're building your first app — watch this before you write another line of code.In this video, Steve P. Young reveals:✅ The #1 mistake app founders make when building their first app✅ The simplest MVP formula that actually drives revenue — not downloads✅ Why distribution matters more than features✅ How to build your Minimum Viable Revenue (MVR), not just an MVP✅ Real-world examples of indie apps making $3K–$200K/month doing one thing really wellWhether you're a developer or entrepreneur, this is your roadmap to launching an app that makes money from day one — without wasting $30K on the wrong features.